Short answer
ACADIA PHARMACEUTICALS INC (ACAD) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $308M (up 16.4% year over year) with net income of $32M.
Q2 2026 key financials · XBRL
- Revenue
- $308M
- +16.4% YoY · +14.9% QoQ
- Net income
- $32M
- +18.1% YoY · +766.1% QoQ
- Operating margin
- 12.3%
- EPS (diluted)
- $0.18
- +12.5% YoY · +800.0% QoQ
Source: XBRL data from the ACADIA PHARMACEUTICALS INC (ACAD) Q2 2026 10-Q on SEC EDGAR. USD.
ACADIA PHARMACEUTICALS INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly product revenue $308.0M, up $43.4M from $264.6M YoY
- DAYBUE products strongest growth: $124.8M vs $96.1M YoY, up $28.7M
- NUPLAZID revenue $183.2M vs $168.5M YoY, up $14.7M
- Cost margin 91% vs 92% YoY, with cost of sales $28.3M vs $20.7M
- R&D $81.6M vs $78.0M; SG&A $160.3M vs $133.5M, driven by commercial investments
Risk Factors
- EU HTA Regulation effective January 12, 2025, creating evolving evidence requirements and potential reimbursement delays
- DAYBUE post-marketing obligations: FDA released one of five PMRs and three fulfilled, with remaining studies potentially prompting label changes
- NUPLAZID commercialization exposed to boxed-warning perceptions and FDA concerns over prescribing patterns
- Limited specialty-distributor and pharmacy network creating near-term product-access and profitability risk
- Future financing needs could constrain research, development, commercial and manufacturing efforts if capital remains unavailable
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ACADIA PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.